Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of age.
A total of 236 infants received a fourth Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) dose at 12 to 15 months. One month later, the proportion with anti-PRP antibody > or =1.0 microg/mL and bactericidal titers > or =1:8 to MenC and MenY was 98.9%, 96.9%, and 95.4%, respectively. One year later, anti-PRP concentrations > or =0.15 microg/mL, and MenC and MenY bactericidal titers > or =1:8 persisted in 100%, 96.6%, and 83.8%, respectively. The safety profile of HibMenCY was comparable to Hib.
Marshall
Gary S
GS
Department of Pediatrics, University of Louisville School of Medicine, Louisville, KY 40202, USA. gsmars01@louisville.edu
Marchant
Colin D
CD
Blatter
Mark
M
Aris
Emmanuel
E
Boutriau
Dominique
D
Poolman
Jan T
JT
Friedland
Leonard R
LR
Miller
Jacqueline M
JM
D000907:Antibodies, Bacterial / Q000276:immunology*; D018073:Haemophilus Vaccines / Q000009:adverse effects / Q000276:immunology*; D006801:Humans; D007117:Immunization, Secondary / Q000379:methods*; D007223:Infant; D008137:Longitudinal Studies; D050296:Microbial Viability / Q000276:immunology; D013745:Tetanus Toxoid / Q000009:adverse effects / Q000276:immunology*; D013997:Time Factors; D014611:Vaccination / Q000379:methods*; D018074:Vaccines, Conjugate / Q000009:adverse effects / Q000276:immunology
D000907:Antibodies, Bacterial; D018073:Haemophilus Vaccines; C527605:Hib-MenCY-TT vaccine; D013745:Tetanus Toxoid; D018074:Vaccines, Conjugate